1
|
Torre LA, Islami F, Siegel RL, Ward EM and
Jemal A: Global cancer in women: Burden and Trends. Cancer
Epidemiol Biomarkers Prev. 26:444–457. 2017. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
3
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Li X, Zhang R, Liu Z, Li S and Xu H: The
genetic variants in the PTEN/PI3K/AKT pathway predict
susceptibility and CE(A)F chemotherapy response to breast cancer
and clinical outcomes. Oncotarget. 8:20252–20265. 2017.PubMed/NCBI
|
5
|
Jiang BH and Liu LZ: PI3K/PTEN signaling
in angiogenesis and tumorigenesis. Adv Cancer Res. 102:19–65. 2009.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Hall G, Lane BM, Khan K, Pediaditakis I,
Xiao J, Wu G, Wang L, Kovalik ME, Chryst-Stangl M, Davis EE, et al:
The Human FSGS-causing ANLN R431C mutation induces dysregulated
PI3K/AKT/mTOR/Rac1 signaling in podocytes. J Am Soc Nephrol.
29:2110–2122. 2018. View Article : Google Scholar : PubMed/NCBI
|
7
|
Suzuki C, Daigo Y, Ishikawa N, Kato T,
Hayama S, Ito T, Tsuchiya E and Nakamura Y: ANLN plays a critical
role in human lung carcinogenesis through the activation of RHOA
and by involvement in the phosphoinositide 3-kinase/AKT pathway.
Cancer Res. 65:11314–11325. 2005. View Article : Google Scholar : PubMed/NCBI
|
8
|
Huber TB, Hartleben B, Kim J, Schmidts M,
Schermer B, Keil A, Egger L, Lecha RL, Borner C, Pavenstädt H, et
al: Nephrin and CD2AP associate with phosphoinositide 3-OH kinase
and stimulate AKT-dependent signaling. Mol Cell Biol. 23:4917–4928.
2003. View Article : Google Scholar : PubMed/NCBI
|
9
|
Zhou W, Wang Z, Shen N, Pi W, Jiang W,
Huang J, Hu Y, Li X and Sun L: Knockdown of ANLN by lentivirus
inhibits cell growth and migration in human breast cancer. Mol Cell
Biochem. 398:11–19. 2015. View Article : Google Scholar : PubMed/NCBI
|
10
|
Magnusson K, Gremel G, Rydén L, Pontén V,
Uhlén M, Dimberg A, Jirström K and Pontén F: ANLN is a prognostic
biomarker independent of Ki-67 and essential for cell cycle
progression in primary breast cancer. BMC Cancer. 16:9042016.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Ciruelos Gil EM: Targeting the
PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Cancer Treat Rev. 40:862–871. 2014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Guo S, Colbert LS, Fuller M, Zhang Y and
Gonzalez-Perez RR: Vascular endothelial growth factor receptor-2 in
breast cancer. Biochim Biophys Acta. 1806:108–121. 2010.PubMed/NCBI
|
13
|
Takahashi Y, Kitadai Y, Bucana CD, Cleary
KR and Ellis LM: Expression of vascular endothelial growth factor
and its receptor, KDR, correlates with vascularity, metastasis, and
proliferation of human colon cancer. Cancer Res. 55:3964–3968.
1995.PubMed/NCBI
|
14
|
Mahdi KM, Nassiri MR and Nasiri K:
Hereditary genes and SNPs associated with breast cancer. Asian Pac
J Cancer Prev. 14:3403–3409. 2013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Nelson MR, Marnellos G, Kammerer S, Hoyal
CR, Shi MM, Cantor CR and Braun A: Large-scale validation of single
nucleotide polymorphisms in gene regions. Genome Res. 14:1664–1668.
2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Deng N, Zhou H, Fan H and Yuan Y: Single
nucleotide polymorphisms and cancer susceptibility. Oncotarget.
8:110635–110649. 2017. View Article : Google Scholar : PubMed/NCBI
|
17
|
Beltran H, Prandi D, Mosquera JM, Benelli
M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV,
Varambally S, et al: Divergent clonal evolution of
castration-resistant neuroendocrine prostate cancer. Nat Med.
22:298–305. 2016. View Article : Google Scholar : PubMed/NCBI
|
18
|
Cancer Genome Atlas Research, Network, .
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
19
|
Long X, Zhou W, Wang Y and Liu S:
Prognostic significance of ANLN in lung adenocarcinoma. Oncol Lett.
16:1835–1840. 2018.PubMed/NCBI
|
20
|
Dong G, Guo X, Fu X, Wan S, Zhou F, Myers
RE, Bao G, Burkart A, Yang H and Xing J: Potentially functional
genetic variants in KDR gene as prognostic markers in patients with
resected colorectal cancer. Cancer Sci. 103:561–568. 2012.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Garrigós C, Espinosa M, Salinas A, Osman
I, Medina R, Taron M, Molina-Pinelo S and Duran I: Single
nucleotide polymorphisms as prognostic and predictive biomarkers in
renal cell carcinoma. Oncotarget. 8:106551–106564. 2017. View Article : Google Scholar : PubMed/NCBI
|
22
|
Slattery ML, Lundgreen A and Wolff RK:
VEGFA, FLT1, KDR and colorectal cancer: Assessment of disease risk,
tumor molecular phenotype, and survival. Mol Carcinog. 53 (Suppl
1):E140–E150. 2013. View Article : Google Scholar : PubMed/NCBI
|
23
|
Wu IC, Zhao Y, Zhai R, Liu G,
Ter-Minassian M, Asomaning K, Su L, Liu CY, Chen F, Kulke MH, et
al: Association between polymorphisms in cancer-related genes and
early onset of esophageal adenocarcinoma. Neoplasia. 13:386–392.
2011. View Article : Google Scholar : PubMed/NCBI
|
24
|
Miao C, Cao J, Wang Y, Liu B and Wang Z:
Effects of VEGF and VEGFR polymorphisms on the outcome of patients
with metastatic renal cell carcinoma treated with sunitinib: A
systematic review and meta-analysis. Oncotarget. 8:68854–68862.
2017. View Article : Google Scholar : PubMed/NCBI
|
25
|
Beeghly-Fadiel A, Shu XO, Lu W, Long J,
Cai Q, Xiang YB, Zheng Y, Zhao Z, Gu K, Gao YT and Zheng W: Genetic
variation in VEGF family genes and breast cancer risk: A report
from the Shanghai Breast Cancer Genetics Study. Cancer Epidemiol
Biomarkers Prev. 20:33–41. 2011. View Article : Google Scholar : PubMed/NCBI
|
26
|
Sherry ST, Ward MH, Kholodov M, Baker J,
Phan L, Smigielski EM and Sirotkin K: dbSNP: The NCBI database of
genetic variation. Nucleic Acids Res. 29:308–311. 2001. View Article : Google Scholar : PubMed/NCBI
|
27
|
Therneau T: A package for survival
analysis in S. version 2.38. https://CRAN.Rproject.org/package=survival2015
|
28
|
R Development Core Team, . R: A language
and environment for statistical computing. R Foundation for
Statistical Computing. 2009, https://www.gbif.org/tool/81287/r-a-language-and-environment-for-statistical-computing
|
29
|
Nicolae DL, Gamazon E, Zhang W, Duan S,
Dolan ME and Cox NJ: Trait-associated SNPs are more likely to be
eQTLs: Annotation to enhance discovery from GWAS. PLoS Genet.
6:e10008882010. View Article : Google Scholar : PubMed/NCBI
|
30
|
Bendl J, Musil M, Štourač J, Zendulka J,
Damborský J and Brezovský J: PredictSNP2: A unified platform for
accurately evaluating SNP effects by exploiting the different
characteristics of variants in distinct genomic regions. PLoS
Comput Biol. 12:e10049622016. View Article : Google Scholar : PubMed/NCBI
|
31
|
Fu Y, Liu Z, Lou S, Bedford J, Mu XJ, Yip
KY, Khurana E and Gerstein M: FunSeq2: A framework for prioritizing
noncoding regulatory variants in cancer. Genome Biol. 15:4802014.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Kircher M, Witten DM, Jain P, O'Roak BJ,
Cooper GM and Shendure J: A general framework for estimating the
relative pathogenicity of human genetic variants. Nat Genet.
46:310–315. 2014. View Article : Google Scholar : PubMed/NCBI
|
33
|
Quang D, Chen Y and Xie X: DANN: A deep
learning approach for annotating the pathogenicity of genetic
variants. Bioinformatics. 31:761–763. 2015. View Article : Google Scholar : PubMed/NCBI
|
34
|
Ritchie GR, Dunham I, Zeggini E and Flicek
P: Functional annotation of noncoding sequence variants. Nat
Methods. 11:294–296. 2014. View Article : Google Scholar : PubMed/NCBI
|
35
|
Kanehisa M, Araki M, Goto S, Hattori M,
Hirakawa M, Itoh M, Katayama T, Kawashima S, Okuda S, Tokimatsu T
and Yamanishi Y: KEGG for linking genomes to life and the
environment. Nucleic Acids Res 36 (Database Issue). D480–D484.
2008.
|
36
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
37
|
Carlson M: org.Hs.eg.db: Genome wide
annotation for Human. 2019.
|
38
|
Franz M, Rodriguez H, Lopes C, Zuberi K,
Montojo J, Bader GD and Morris Q: GeneMANIA update 2018. Nucleic
Acids Res. 46:W60–W64. 2018. View Article : Google Scholar : PubMed/NCBI
|
39
|
Warde-Farley D, Donaldson SL, Comes O,
Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT,
et al: The GeneMANIA prediction server: Biological network
integration for gene prioritization and predicting gene function.
Nucleic Acids Res. 38:W214–W220. 2010. View Article : Google Scholar : PubMed/NCBI
|
40
|
Labun K, Montague TG, Krause M, Torres
Cleuren YN, Tjeldnes H and Valen E: CHOPCHOP v3: Expanding the
CRISPR web toolbox beyond genome editing. Nucleic Acids Res.
47:W171–W174. 2019. View Article : Google Scholar : PubMed/NCBI
|
41
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
42
|
Heiskanen MA, Bittner ML, Chen Y, Khan J,
Adler KE, Trent JM and Meltzer PS: Detection of gene amplification
by genomic hybridization to cDNA microarrays. Cancer Res.
60:799–802. 2000.PubMed/NCBI
|
43
|
Li H, Jie S, Zou P and Zou G: CDNA
microarray analysis of chronic myeloid leukemia. Int J Hematol.
75:388–393. 2002. View Article : Google Scholar : PubMed/NCBI
|
44
|
Brouhard GJ and Rice LM: Microtubule
dynamics: An interplay of biochemistry and mechanics. Nat Rev Mol
Cell Biol. 19:451–463. 2018. View Article : Google Scholar : PubMed/NCBI
|
45
|
Dogra N, Kumar A and Mukhopadhyay T:
Fenbendazole acts as a moderate microtubule destabilizing agent and
causes cancer cell death by modulating multiple cellular pathways.
Sci Rep. 8:119262018. View Article : Google Scholar : PubMed/NCBI
|
46
|
Parker AL, Kavallaris M and McCarroll JA:
Microtubules and their role in cellular stress in cancer. Front
Oncol. 4:1532014. View Article : Google Scholar : PubMed/NCBI
|
47
|
Williams GH and Stoeber K: The cell cycle
and cancer. J Pathol. 226:352–364. 2012. View Article : Google Scholar : PubMed/NCBI
|
48
|
Visochek L, Castiel A, Mittelman L, Elkin
M, Atias D, Golan T, Izraeli S, Peretz T and Cohen-Armon M:
Exclusive destruction of mitotic spindles in human cancer cells.
Oncotarget. 8:20813–20824. 2017. View Article : Google Scholar : PubMed/NCBI
|
49
|
Dong X, Liu F, Sun L, Liu M, Li D, Su D,
Zhu Z, Dong JT, Fu L and Zhou J: Oncogenic function of microtubule
end-binding protein 1 in breast cancer. J Pathol. 220:361–369.
2010.PubMed/NCBI
|
50
|
Liu M, Wang X, Yang Y, Li D, Ren H, Zhu Q,
Chen Q, Han S, Hao J and Zhou J: Ectopic expression of the
microtubule-dependent motor protein Eg5 promotes pancreatic
tumourigenesis. J Pathol. 221:221–228. 2010. View Article : Google Scholar : PubMed/NCBI
|
51
|
McCusker C, Upton J and Warrington R:
Primary immunodeficiency. Allergy Asthma Clin Immunol. 14 (Suppl
2):S612018. View Article : Google Scholar
|
52
|
Shapiro RS: Malignancies in the setting of
primary immunodeficiency: Implications for
hematologists/oncologists. Am J Hematol. 86:48–55. 2011. View Article : Google Scholar : PubMed/NCBI
|
53
|
Filipovich AH, Mathur A, Kamat D and
Shapiro RS: Primary immunodeficiencies: Genetic risk factors for
lymphoma. Cancer Res 52 (19 Suppl). 5465S–5467S. 1992.
|
54
|
Moriwaki Y, Yamamoto T and Higashino K:
Enzymes involved in purine metabolism-a review of histochemical
localization and functional implications. Histol Histopathol.
14:1321–1340. 1999.PubMed/NCBI
|
55
|
Chen TC, Lin KT, Chen CH, Lee SA, Lee PY,
Liu YW, Kuo YL, Wang FS, Lai JM and Huang CY: Using an in situ
proximity ligation assay to systematically profile endogenous
protein-protein interactions in a pathway network. J Proteome Res.
13:5339–5346. 2014. View Article : Google Scholar : PubMed/NCBI
|
56
|
Hein MY, Hubner NC, Poser I, Cox J,
Nagaraj N, Toyoda Y, Gak IA, Weisswange I, Mansfeld J, Buchholz F,
et al: A human interactome in three quantitative dimensions
organized by stoichiometries and abundances. Cell. 163:712–723.
2015. View Article : Google Scholar : PubMed/NCBI
|
57
|
Xie YG, Yu Y, Hou LK, Wang X, Zhang B and
Cao XC: FYN promotes breast cancer progression through
epithelial-mesenchymal transition. Oncol Rep. 36:1000–1006. 2016.
View Article : Google Scholar : PubMed/NCBI
|
58
|
Lee GH, Yoo KC, An Y, Lee HJ, Lee M, Uddin
N, Kim MJ, Kim IG, Suh Y and Lee SJ: FYN promotes mesenchymal
phenotypes of basal type breast cancer cells through STAT5/NOTCH2
signaling node. Oncogene. 37:1857–1868. 2018. View Article : Google Scholar : PubMed/NCBI
|
59
|
Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J
and Shi B: Breast cancer intrinsic subtype classification, clinical
use and future trends. Am J Cancer Res. 5:2929–2943.
2015.PubMed/NCBI
|
60
|
Dai X, Xiang L, Li T and Bai Z: Cancer
hallmarks, biomarkers and breast cancer molecular subtypes. J
Cancer. 7:1281–1294. 2016. View Article : Google Scholar : PubMed/NCBI
|